Skip to content

Nevus Doctor Clinical Decision Support for GPs

Nevus or Melanoma? Nevus Doctor - Computer Aided Clinical Decision Support in Primary Health Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03246412
Enrollment
35
Registered
2017-08-11
Start date
2018-01-17
Completion date
2019-12-12
Last updated
2024-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actinic Keratoses, Melanoma (Skin), Non-melanoma Skin Cancer

Brief summary

The study investigates if a computer-based clinical decision support tool for skin cancer may improve the diagnostic accuracy of general practitioners (GPs). The aim of the program is to help GPs increase their diagnostic accuracy, in particular regarding the selection of suspicious skin lesions that need biopsy or referral to specialist health care for further assessment. Half of the physicians in the trial will have the clinical decision support tool available during consultations, while the other half has no such tool available. We hypothesize that general practitioners using the clinical decision support tool will have a higher number of correct classifications of skin lesions compared to doctors without the tool.

Detailed description

General practitioners (GPs) examine patients who attend a primary health care center. In the intervention group the computer-based clinical decision support tool Nevus doctor in a first step assists doctors in the process of selecting skin lesions that are suggestive of cancer. In the next step a given skin lesion is photographed using a dermatoscope attached to the lens of the camera. The dermatoscopic image is then processed by the computer program Nevus doctor and a preliminary result is presented. Finally the GP reviews the result and assesses the clinical significance of the output by using guidelines presented by Nevus doctor. The patient is subsequently referred to a dermatologist and a complete skin examination is performed. The assessment of the dermatologist serves as the gold standard.

Interventions

DIAGNOSTIC_TESTNevus doctor clinical decision support

The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.

Sponsors

University Hospital of North Norway
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No

Inclusion criteria

* Patients concerned about one or several skin lesion(s) * Patients with any other condition if doctor has observed a skin lesion suspicious for skin cancer (incl. actinic keratosis)

Exclusion criteria

* Patients not able to give consent

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic classification of suspicious skin lesionsUp to 3 monthsSkin lesions selected by the GP are classified into three classes: 1 Not suspicious for skin cancer, 2 Somewhat suspicious for skin cancer, 3 Very suspicious for skin cancer. The reference standard is the specialist's classification. The number of correct classifications are counted. Sensitivity and specificity scores are calculated.

Secondary

MeasureTime frameDescription
Skin lesions not classified by GPsUp to 3 monthsSkin lesions that were not selected by the GP but were later classified by the specialist to be suspicious for skin cancer or very suspicious for skin cancer are counted.
Biopsies and excisionsUp to 3 monthsSkin lesions biopsied or excised by the GP are counted.

Other

MeasureTime frameDescription
User experienceUp to 12 months.The GPs are asked to answer a questionnaire to assess the user experiences of operating the clinical decision support tool.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026